English

Tenax Therapeutics, Inc.

EDGAR

TENX Quarterly report (10-Q) · filed 2026-07-31

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026-06-30 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-14.2 million USD

2026-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -23500000 USD Source
Operating Cash Flow: -9300000 USD Source

Cash and cash equivalents: 118 million USD 2026-06-30 Source
Exact value

118000000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 31.9 million shares 2026-06-30 Source
Exact value

31949785 shares

Reported share-count change

670.15% · 27.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

4148495 shares · 2025-06-30· Source
31949785 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2025-01-01 – 2025-06-30 Source
Revenue: 0 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-01-01 – 2026-06-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source

Net income

-64.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -15804000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -52599000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -37059000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -15716000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -17803000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-07-31.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2022-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Tenax Therapeutics, Inc. · 2025-12-31 Tenax Therapeutics, Inc. (edgar:34956) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2620389 Filing: 000119312526099393 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000095017025044398/tennx-20241231.htm#2449981 Filing: 000095017025044398
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 35 million

Prior period

−USD 17.6 million

2024-01-01 – 2024-12-31
Current period

−USD 52.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-52599000 − -17602000 = -34997000 USD

-17602000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-52599000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Tenax Therapeutics, Inc. · 2025-12-31 Tenax Therapeutics, Inc. (edgar:34956) Year-over-year change in Net income: -34997000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -52599000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2671947 Filing: 000119312526099393 Input fundies:NetIncome: -17602000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2673854 Filing: 000119312526099393
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 21 million

Prior period

−USD 14.8 million

2024-01-01 – 2024-12-31
Current period

−USD 35.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-35800000 − -14800000 = -21000000 USD

-14800000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-35800000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Tenax Therapeutics, Inc. · 2025-12-31 Tenax Therapeutics, Inc. (edgar:34956) Year-over-year change in Operating cash flow: -21000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -35800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2676383 Filing: 000119312526099393 Input fundies:OperatingCashFlow: -14800000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2677226 Filing: 000119312526099393
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 56.39 million
Operating income −USD 56.39 million
Tax, interest and other Derived −USD 3.79 million
Net income −USD 52.6 million

Cash

Operating cash flow −USD 35.8 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	52650739 Derived	-52650739	-8726835 Derived	-43923904	-15874184 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -52650739 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -43923904 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -15871300 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2884 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	19494000 Derived	-19494000	-1892000 Derived	-17602000	Unavailable	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -19494000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -17602000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -14800000 USD Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	56385000 Derived	-56385000	-3786000 Derived	-52599000	Unavailable	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -56385000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -52599000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -35800000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20162016-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source
20252025-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -52650739 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -19494000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -56385000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -43923904 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -17602000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -52599000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -15871300 Open source Capital Expenditure: 2884 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -14800000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -35800000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -35.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-15871300	Operating Cash Flow: -15871300 Open source
20242024-12-31	Operating cash flow	-14800000	Operating Cash Flow: -14800000 Open source
20252025-12-31	Operating cash flow	-35800000	Operating Cash Flow: -35800000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -15.9M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-15874184	Operating Cash Flow: -15871300 Open source Capital Expenditure: 2884 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -14800000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -35800000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	26.6%	Total Liabilities: 6199237 Open source Total Assets: 23340175 Open source
20242024-12-31	Liabilities / assets	4.9%	Total Liabilities: 4693000 Open source Total Assets: 96686000 Open source
20252025-12-31	Liabilities / assets	6.9%	Total Liabilities: 7156000 Open source Total Assets: 104227000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

14.56× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	2.2×	Current Assets: 13628175 Open source Current Liabilities: 6199237 Open source
20242024-12-31	Current assets / current liabilities	20.6×	Current Assets: 96686000 Open source Current Liabilities: 4693000 Open source
20252025-12-31	Current assets / current liabilities	14.56×	Current Assets: 104227000 Open source Current Liabilities: 7156000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 43.92 million Exact value Exact value: -43923904 USD 2016-01-01 – 2016-12-31: -43923904 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2016-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -43923904 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43923904 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495418003517/tenx-20171231.xml#38390 Filing: 000165495418003517 The citation records this snapshot. The page link may show a newer release later.	−USD 15.87 million Exact value Exact value: -15871300 USD 2016-01-01 – 2016-12-31: -15871300 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2016-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -15871300 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15871300 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495418003517/tenx-20171231.xml#55246 Filing: 000165495418003517 The citation records this snapshot. The page link may show a newer release later.	USD 2,884 Exact value Exact value: 2884 USD 2016-01-01 – 2016-12-31: 2884 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2016-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 2884 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2884 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495418003517/tenx-20171231.xml#56255 Filing: 000165495418003517 The citation records this snapshot. The page link may show a newer release later.	−USD 15.87 million Calculation and evidence -15871300 − 2884 USD Exact free cash flow: -15874184 USD 2016-01-01 – 2016-12-31: -15871300 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2884 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2016-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -15874184 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15871300 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495418003517/tenx-20171231.xml#55246 Filing: 000165495418003517 Input fundies:CapitalExpenditure: 2884 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495418003517/tenx-20171231.xml#56255 Filing: 000165495418003517 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 8.84 million Exact value Exact value: -8839682 USD 2017-01-01 – 2017-12-31: -8839682 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2017-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -8839682 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8839682 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495419003861/tenx-20181231.xml#50301 Filing: 000165495419003861 The citation records this snapshot. The page link may show a newer release later.	−USD 12.14 million Exact value Exact value: -12140517 USD 2017-01-01 – 2017-12-31: -12140517 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2017-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -12140517 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12140517 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495419003861/tenx-20181231.xml#58354 Filing: 000165495419003861 The citation records this snapshot. The page link may show a newer release later.	USD 4,537 Exact value Exact value: 4537 USD 2017-01-01 – 2017-12-31: 4537 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2017-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 4537 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4537 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495419003861/tenx-20181231.xml#59361 Filing: 000165495419003861 The citation records this snapshot. The page link may show a newer release later.	−USD 12.15 million Calculation and evidence -12140517 − 4537 USD Exact free cash flow: -12145054 USD 2017-01-01 – 2017-12-31: -12140517 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4537 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2017-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -12145054 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12140517 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495419003861/tenx-20181231.xml#58354 Filing: 000165495419003861 Input fundies:CapitalExpenditure: 4537 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495419003861/tenx-20181231.xml#59361 Filing: 000165495419003861 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 14.14 million Exact value Exact value: -14144049 USD 2018-01-01 – 2018-12-31: -14144049 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2018-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -14144049 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14144049 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495420003498/tenx-20191231.xml#60645 Filing: 000165495420003498 The citation records this snapshot. The page link may show a newer release later.	−USD 5.5 million Exact value Exact value: -5499461 USD 2018-01-01 – 2018-12-31: -5499461 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2018-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -5499461 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5499461 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495420003498/tenx-20191231.xml#74813 Filing: 000165495420003498 The citation records this snapshot. The page link may show a newer release later.	USD 7,595 Exact value Exact value: 7595 USD 2018-01-01 – 2018-12-31: 7595 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2018-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 7595 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7595 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495420003498/tenx-20191231.xml#75818 Filing: 000165495420003498 The citation records this snapshot. The page link may show a newer release later.	−USD 5.51 million Calculation and evidence -5499461 − 7595 USD Exact free cash flow: -5507056 USD 2018-01-01 – 2018-12-31: -5499461 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 7595 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2018-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -5507056 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5499461 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495420003498/tenx-20191231.xml#74813 Filing: 000165495420003498 Input fundies:CapitalExpenditure: 7595 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495420003498/tenx-20191231.xml#75818 Filing: 000165495420003498 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 8.39 million Exact value Exact value: -8394363 USD 2019-01-01 – 2019-12-31: -8394363 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2019-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -8394363 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8394363 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495421004297/tenx-20201231.xml#66539 Filing: 000165495421004297 The citation records this snapshot. The page link may show a newer release later.	−USD 7.56 million Exact value Exact value: -7556177 USD 2019-01-01 – 2019-12-31: -7556177 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2019-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -7556177 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7556177 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495421004297/tenx-20201231.xml#70834 Filing: 000165495421004297 The citation records this snapshot. The page link may show a newer release later.	USD 3,574 Exact value Exact value: 3574 USD 2019-01-01 – 2019-12-31: 3574 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2019-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 3574 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3574 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495421004297/tenx-20201231.xml#71838 Filing: 000165495421004297 The citation records this snapshot. The page link may show a newer release later.	−USD 7.56 million Calculation and evidence -7556177 − 3574 USD Exact free cash flow: -7559751 USD 2019-01-01 – 2019-12-31: -7556177 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3574 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2019-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -7559751 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7556177 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495421004297/tenx-20201231.xml#70834 Filing: 000165495421004297 Input fundies:CapitalExpenditure: 3574 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495421004297/tenx-20201231.xml#71838 Filing: 000165495421004297 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 9.85 million Exact value Exact value: -9851391 USD 2020-01-01 – 2020-12-31: -9851391 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2020-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -9851391 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9851391 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423000693/tenx_s1.htm#1217696 Filing: 000165495423000693 The citation records this snapshot. The page link may show a newer release later.	−USD 9.27 million Exact value Exact value: -9272856 USD 2020-01-01 – 2020-12-31: -9272856 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2020-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -9272856 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9272856 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423000693/tenx_s1.htm#1331940 Filing: 000165495423000693 The citation records this snapshot. The page link may show a newer release later.	USD 3,490 Exact value Exact value: 3490 USD 2020-01-01 – 2020-12-31: 3490 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2020-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 3490 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3490 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423000693/tenx_s1.htm#1304423 Filing: 000165495423000693 The citation records this snapshot. The page link may show a newer release later.	−USD 9.28 million Calculation and evidence -9272856 − 3490 USD Exact free cash flow: -9276346 USD 2020-01-01 – 2020-12-31: -9272856 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3490 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2020-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -9276346 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9272856 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423000693/tenx_s1.htm#1331940 Filing: 000165495423000693 Input fundies:CapitalExpenditure: 3490 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423000693/tenx_s1.htm#1304423 Filing: 000165495423000693 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 32.47 million Exact value Exact value: -32474358 USD 2021-01-01 – 2021-12-31: -32474358 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2021-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -32474358 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32474358 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#817717 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.	−USD 10.86 million Exact value Exact value: -10856203 USD 2021-01-01 – 2021-12-31: -10856203 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2021-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -10856203 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10856203 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#936903 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.	USD 5,252 Exact value Exact value: 5252 USD 2021-01-01 – 2021-12-31: 5252 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2021-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 5252 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5252 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#943616 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.	−USD 10.86 million Calculation and evidence -10856203 − 5252 USD Exact free cash flow: -10861455 USD 2021-01-01 – 2021-12-31: -10856203 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 5252 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2021-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -10861455 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10856203 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#936903 Filing: 000165495423003945 Input fundies:CapitalExpenditure: 5252 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#943616 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 11.05 million Exact value Exact value: 11047895 USD 2022-01-01 – 2022-12-31: 11047895 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2022-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: 11047895 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 11047895 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495424003827/tenx_10k.htm#1029022 Filing: 000165495424003827 The citation records this snapshot. The page link may show a newer release later.	−USD 11.39 million Exact value Exact value: -11388571 USD 2022-01-01 – 2022-12-31: -11388571 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2022-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -11388571 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11388571 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495424003827/tenx_10k.htm#1132074 Filing: 000165495424003827 The citation records this snapshot. The page link may show a newer release later.	USD 2,323 Exact value Exact value: 2323 USD 2022-01-01 – 2022-12-31: 2323 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Tenax Therapeutics, Inc. · 2022-12-31 Tenax Therapeutics, Inc. (edgar:34956) Capital Expenditure: 2323 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2323 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#942947 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.	−USD 11.39 million Calculation and evidence -11388571 − 2323 USD Exact free cash flow: -11390894 USD 2022-01-01 – 2022-12-31: -11388571 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 2323 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Tenax Therapeutics, Inc. · 2022-12-31 Tenax Therapeutics, Inc. (edgar:34956) Free cash flow: -11390894 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11388571 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495424003827/tenx_10k.htm#1132074 Filing: 000165495424003827 Input fundies:CapitalExpenditure: 2323 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000165495423003945/tenx_10k.htm#942947 Filing: 000165495423003945 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 7.71 million Exact value Exact value: -7711000 USD 2023-01-01 – 2023-12-31: -7711000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2023-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -7711000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7711000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000095017025044398/tennx-20241231.htm#2498327 Filing: 000095017025044398 The citation records this snapshot. The page link may show a newer release later.	−USD 5.9 million Exact value Exact value: -5900000 USD 2023-01-01 – 2023-12-31: -5900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2023-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -5900000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5900000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000095017025044398/tennx-20241231.htm#2501888 Filing: 000095017025044398 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 17.6 million Exact value Exact value: -17602000 USD 2024-01-01 – 2024-12-31: -17602000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2024-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -17602000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17602000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2673854 Filing: 000119312526099393 The citation records this snapshot. The page link may show a newer release later.	−USD 14.8 million Exact value Exact value: -14800000 USD 2024-01-01 – 2024-12-31: -14800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2024-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -14800000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14800000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2677226 Filing: 000119312526099393 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 52.6 million Exact value Exact value: -52599000 USD 2025-01-01 – 2025-12-31: -52599000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Tenax Therapeutics, Inc. · 2025-12-31 Tenax Therapeutics, Inc. (edgar:34956) Net Income: -52599000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52599000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2671947 Filing: 000119312526099393 The citation records this snapshot. The page link may show a newer release later.	−USD 35.8 million Exact value Exact value: -35800000 USD 2025-01-01 – 2025-12-31: -35800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Tenax Therapeutics, Inc. · 2025-12-31 Tenax Therapeutics, Inc. (edgar:34956) Operating Cash Flow: -35800000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/34956/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm#2676383 Filing: 000119312526099393 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

151 filings · 4,021 latest values · 4,021 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000034956, 34956, TENX, edgar:34956

Also known as OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, TENAX THERAPEUTICS, INC, TENAX THERAPEUTICS, INC., TENAX THERAPEUTICS, INC. , Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation